PCSK9 drug's Ph. III results show potent effects on lipids

Share this article:

Sanofi/Regeneron's highly touted PCSK9 inhibitor, alirocumab, cut LDL "bad" cholesterol by half in the ODYSSEY MONO trial. ODYSSEY MONO is the first study to report data from the 12 Phase III trials that have been initiated so far as part of the more than 23,000 patient ODYSSEY clinical trial program.

In the release, Jay Edelberg, head of the PCSK9 development and launch unit of Sanofi Group said, "We are excited with the findings from the first Phase III trial with alirocumab.  While the majority of our clinical program is investigating alirocumab in combination with lipid-lowering therapies, these monotherapy results are encouraging."
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.